Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes... [including commentary by Raymond Plodkowski].
BACKGROUND: It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes mellitus is characterized by insulin resistance and insulin secretion impairment leading to hyperglycemia. The presence of...
| Publicado en: | American Health & Drug Benefits Vol. 10; no. 4; pp. 178 - 189 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | commentary research tables/charts Journal Article |
| Publicado: |
Amplity Health
Jun2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |